Table 3. Pharmacokinetics of Selected Compounds^a.

		dose
species	compd	iv	po	CL	Vd	t1/2	DNAUCpo	F
ratb	2	0.5e	10	91.2	4.42	0.72	37.7	3.6
	19	0.5e		45.9	2.1	0.62
	20	2	5	1.88	0.81	5.20	1293	14.5
	21	0.5	8.6	3.48	0.97	3.89	6651	133
mousec	21	1	3	1.44	1.34	10.9	5831	37.1
dogd	21	1	2	3.15	2.12		2937	52.2

^aDose: mg/kg; CL: mL/min/kg; Vd: L/kg; DNAUC_po: (ng*h/mL)/(mg/kg); t_1/2: hour; F: %, n ≥ 2. For compound 21: rat iv formulation: 1.00 mg/mL in DMSO:PEG400:Water (10:45:45), po formulation: 2.00 mg/mL in 1% HPMC/water(1:1). Mouse iv formulation: 1 mg/mL in 20%HP-beta-CD in saline, pH = 8, po formulation: 3 mg/mL in 0.5% HPMC. Dog iv Formulation: 0.25 mg/mL in 5% DMSO:20% HP-Beta-CD in saline, po formulation: 0.5 mg/mL in 5% DMSO:6% HP-β-CD in saline, pH 10.3.

^bSprague–Dawley rats, fasted.

^cMale C57 mouse, fasted.

^dMale beagle dogs, fasted.

^eiv: cassette dosing.